Prostatic steroid 5 alpha-reductase, an androgen metabolic gene
Reichardt, J.K.
Mayo Clinic Proceedings 75 Suppl: S36-S39
2000
ISSN/ISBN: 0025-6196 PMID: 10959214 Document Number: 518391
Prostate cancer risk is highest in African Americans, lowest in Asians, and intermediate in Caucasians and Latinos. The data clearly suggest that environmental and genetic factors are involved. Investigation of the genetic factors suggests that allelic variation in the SRD5A2 gene is partially responsible for the striking racial and ethnic variations in risk.
Document emailed within 1 workday
Related Documents
Sun, Z.Y.; Tu, Z.H. 1998: A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia Methods and Findings in Experimental and Clinical Pharmacology 20(4): 283-287Klotz, L.H. 2006: Androgen replacement and/or 5 alpha reductase inhibitors in aging men Canadian Journal of Urology 13(Suppl 1): 44-45
Adiyaman, P.B.; Ocal, G.; Cetinkaya, E.; Akar, N.; Uysal, A.; Duman, T.; Evliyaoğlu, O.; Aycan, Z.; Lumbroso, S.; Sultan, C.; Berberoğlu, M. 2006: 5 alpha steroid reductase deficiency in Turkey Pediatric Endocrinology Reviews: Per 3(Suppl 3): 462-469
Batzold, F.H. 1981: Approaches to prostatic 5 alpha-reductase inhibitors Progress in Clinical and Biological Research 75b: 269-282
Kostyrko, A.; Antkowiak, J.; Warenik-Szymankiewicz, A.; Trzeciak, W.H. 1994: The importance of DNA analysis in the diagnosis of steroid 5-alpha-reductase deficiency Ginekologia Polska 65(7): 400-406
Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168
Tyuzikov, I.A.; Grekov, E.A.; Kalinchenko, S.Y. 2015: Features of Clinical Course and Morphometric Parameters of Benign Prostatic Hyperplasia in Men with Metabolic Syndrome and Androgen Deficiency Urologiia 5: 66-69
Cohen, J.; Ooms, M.P.; Vreeburg, J.T. 1981: Reduction of fertilizing capacity of epididymal spermatozoa by 5 alpha-steroid reductase inhibitors Experientia 37(9): 1031-1032
Germain, P.; Lefebvre, G.; Bena, B.; Gay, R. 1972: In vitro study of characteristics of 5 alpha-delta 4 steroid reductase from Nocardia corallina Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 166(8): 1123-1128
Wu, J-Hui.; Sun, Z-Yue. 2013: Establishment of an in vitro screening model for steroid 5 alpha-reductase inhibitors with the microplate reader Zhonghua Nan Ke Xue 19(6): 483-486
Pino, A.M. 1996: Androgen receptor gene structure and protein function. Gene structural defects that promote androgen resistance in men Revista Medica de Chile 124(9): 1127-1136
Hansen, B.J.; Hvidt, V. 1993: Finasteride. a new 5 alpha reductase inhibitor registered for treatment of benign prostatic hypertrophy with the purpose of avoiding or postponing surgery Ugeskrift for Laeger 155(50): 4110-4112
Denti, L.; Pasolini, G.; Cortellini, P.; Sanfelici, L.; Benedetti, R.; Cecchetti, A.; Ferretti, S.; Banchini, A.; Ablondi, F.; Valenti, G. 1999: Effects of 5 alpha-reductase inhibition by finasteride on lipoproteins and body composition in males affected by benign prostatic hyperplasia (BPH) Journal of Endocrinological Investigation 22(10 Suppl): 70-71
Van Moorselaar, R.J.; Hendriks, B.T.; van Stratum, P.; van der Meide, P.H.; Debruyne, F.M.; Schalken, J.A. 1991: Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumors Cancer Research 51(9): 2329-2334
Reyes, E.F.; Virgo, B.B. 1988: Neonatal programming of ethylmorphine demethylase and corticosteroid 5 alpha-reductase by testosterone, dihydrotestosterone, and estradiol. Effects of an anti-estrogen, an anti-androgen, and an inhibitor of estrogen synthetase Drug Metabolism and Disposition: the Biological Fate of Chemicals 16(1): 93-97
Kazama, T.; Mizuno, I.; Takamine, T.; Umeda, K.; Terada, T.; Ishikawa, S.; Fuse, H.; Katayama, T. 1990: Evaluation of anti-androgen therapy for benign prostatic hypertrophy by using transrectal prostatic ultrasonography Hinyokika Kiyo. Acta Urologica Japonica 36(12): 1423-1427
Westberg, L.; Baghaei, F.; Rosmond, R.; Hellstrand, M.; Landén, M.; Jansson, M.; Holm, G.; Björntorp, P.; Eriksson, E. 2001: Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women Journal of Clinical Endocrinology and Metabolism 86(6): 2562-2568
Krieg, M.; Bartsch, W.; Herzer, S.; Becker, H.; Voigt, K.D. 1977: Quantification of androgen binding, androgen tissue levels, and sex hormone-binding globulin in prostate, muscle and plasma of patients with benign prostatic hypertrophy Acta Endocrinologica 86(1): 200-215
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Lobaccaro, J.M.; Lumbroso, S.; Sultan, C. 1991: Androgen receptor gene polymorphism analysis: application to screening of heterozygote and to prenatal diagnosis of androgen insensitivity syndrome Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 185(6): 422-433